networking-event-for-personalised-digital-health-innovations-in-horizon-2020

1. Horizon 2020
Simon Grattan
11th September 2018
Grant and Funding Manager – Almac Group

2. Overview
• Very brief Almac outline
• My engagement with EU funding
• Why get involved?
• Comments/advice based on my experiences to date

3. “Almac will be the leader in the generation of
superior solutions for the advancement of
human health”
Vision statement
Strategically develop and expand a world class
Group of Companies operating in the
Pharmaceutical and Biotech sectors
Almac Group objective

4. Biomarker
Discovery and
Development
API Services;
Biocatalysis;
Small Molecules
& Peptides
Drug
Product
Development
Analytical
Services
Clinical
Technologies
Specialised Services
Clinical
Services
Commercial
Manufacture
and Pack

5. Unparalleled Expertise & Reach
5,000
Employees globally
17
facilities globally
50+
Years experience
25/25
Work with all top 25
BioPharma companies
All phases
Experience in all phases
of drug development
50%
Contributed to ½ of FDA
approved NME’s in 2016
290
Regulatory & client
audits in 2016
5,400+
Client locations
globally
60+
Network of 60+ in-country
depots for clinical supply

6. Global Group Presence
Our locations
Our depots
Countries we have provided services to in the last 5 years

7. My engagement with EU funding

8. Example projects:
• The Translational Research Network for Prostate
Cancer (TransPot) program will adopt an innovative,
multidisciplinary approach, providing highly sought-
after, effective solutions for incurable prostate
cancer.
• This four year project has received over €2.5m in EU
funding.
• It began in January 2017 with Almac Diagnostics and
QUB as participants in a 10 organisation project
• APPFlow will develop Early Stage Researchers (ESRs)
in innovative research through a focussed training
plan centred on flow chemistry, essential for the
pharmaceutical and fine chemical industries in
Europe.
• This is a 4 year project in the final stages of set up,
supporting 3 PhD students
• Arran Chemical Company (Athlone, Ireland) and QUB
as sole participants, with the Almac Group as a
partner organisation
TransPot

9. Why get involved?
• As a micro-company (SME)
• Cash
• Build the team
• Partners
• Opportunity to develop new
markets
Why not get involved?
• As a micro-company (SME)
• Solely for the cash
• If uncertain of your partners
• If you are looking for a quick to
market approach
• If you struggle with your existing
admin burden

10. Why get involved?
• Almac
• Cash – generous support rate extends to all sizes of partners
• Helps build some of the smaller R&D teams
• Partners can be clients or potentially future clients
• Opportunity to develop new markets – can fund work into an area that
would be deemed too risky for current finite R&D resource

11. Comments/advice based on my experiences to date
• Partners – limit the number and ideally those you’ve already worked with
• Don’t just do it for the cash, there are definitely easier ways
• Don’t get lost in the science, other sections are just as important (to the EC)
• Travel – don’t just stay in NI and expect it all to happen
• Be prepared – have a good accountant and legal person on hand, admin too…
• Register as an expert on the Participant Portal and update profile regularly
• Engage with INI / ITI / NICPs / NCPs etc

12. Thank you
2015
2016
2017
Almac Group – Recent Awards